Head and Neck Squamous Cell Carcinoma Clinical Trials in Fairfax, Virginia

10 studies are recruiting for head and neck squamous cell carcinoma in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, Fairfax, Virginia

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

   This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chem…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Inova Schar Cancer Institute, Fairfax, Virginia

   Locations

   679 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT02734537 on ClinicalTrials.gov

3. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 262771, Fairfax, Virginia

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

4. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

   A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Fairfax, Virginia

   Locations

   13 in total

   Run by

   AstraZeneca

   See if you can join NCT07115043 on ClinicalTrials.gov

5. A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   41 in total

   Run by

   Alentis Therapeutics AG

   See if you can join NCT06747585 on ClinicalTrials.gov

6. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax, Virginia

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

7. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

   This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Texas LLC - Virginia, Fairfax, Virginia

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07503808 on ClinicalTrials.gov

8. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   39 in total

   Run by

   SystImmune Inc.

   See if you can join NCT05983432 on ClinicalTrials.gov

9. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

   A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dren Investigational Site, Fairfax, Virginia

   Locations

   10 in total

   Run by

   Dren Bio

   See if you can join NCT06999187 on ClinicalTrials.gov

10. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, PC, Fairfax, Virginia

    Locations

    16 in total

    Run by

    OncoNano Medicine, Inc.

    See if you can join NCT06022029 on ClinicalTrials.gov